Receptors of peptides as therapeutic targets in epilepsy research

Current Medicinal Chemistry

Volumn 21, Issue 6, 2014, Pages 764-787

  Dobolyi, A ^a,b   Kekesi K A ^b   Juhasz G ^b   Szekely A D ^a   Lovas, G ^c,d   Kovacs Z ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^e UNIVERSITY OF WEST HUNGARY   (Hungary)

Author keywords

Neuromodulation; Neuronal plasticity; Neuropeptide receptors; Seizure; Temporal lobe epilepsy; Therapeutic application

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [3 [N (5 BROMO 2 PYRIDYL) N (3,4 DICHLOROBENZYL)AMINO]PROPYL] 3 [3 (4 IMIDAZOLYL)PROPYL]THIOUREA; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ANGIOTENSIN DERIVATIVE; ANTALARMIN; APREPITANT; BIBO 3226; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CAPTOPRIL; CHOLECYSTOKININ; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLAZOCINE; CYM 2503; CYPRODIME; DYNORPHIN; ENKEPHALIN; GALANIN; GHRELIN; IBUTAMOREN; L 054522; L 779976; L 796778; L 803087; LOSARTAN; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NALTRIBEN; NETAZEPIDE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; OXYTOCIN; PEXACERFONT; PROTIRELIN; RECOMBINANT PROTEIN; RELCOVAPTAN; RP 69758; SOMATOSTATIN; SUBSTANCE P; TABIMORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN; VOFOPITANT; WAY 267464;

ARTICLE; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG TARGETING; EPILEPSY; FRONTAL LOBE EPILEPSY; HUMAN; TEMPORAL LOBE EPILEPSY;

ANIMALS; BLOOD-BRAIN BARRIER; EPILEPSY; HUMANS; MOLECULAR TARGETED THERAPY; NEUROPEPTIDES; RECEPTORS, NEUROPEPTIDE;

EID: 84893284505     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867320666131119154018     Document Type: Article

References (321)

1. Kwan, P.; Brodie, M.J. Drug treatment of epilepsy: When does it fail and how to optimize its use? CNS Spectr, 2004, 9(2), 110-119.
2. Chen, J.W.; Naylor, D.E.; Wasterlain, C.G. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand, 2007, 115(4 Suppl), 7-15.
3. Kobow, K.; Auvin, S.; Jensen, F.; Loscher, W.; Mody, I.; Potschka, H.; Prince, D.; Sierra, A.; Simonato, M.; Pitkanen, A.; Nehlig, A.; Rho, J.M. Finding a better drug for epilepsy: Antiepileptogenesis targets. Epilepsia, 2012, 53(11), 1868-1876.
4. de Lanerolle, N.C.; Brines, M.; Williamson, A.; Kim, J.H.; Spencer, D.D. Neurotransmitters and their receptors in human temporal lobe epilepsy. Epilepsy Res Suppl, 1992, 7, 235-250.
5. Kovac, S.; Walker, M.C. Neuropeptides in epilepsy. Neuropeptides, 2013, 47(6), 467-475.
6. Devlin, A.; Odell, M.; Charlton, J.; Koppel, S. Epilepsy and driving: Current status of research. Epilepsy Res, 2012, 102(3), 135-152.
7. Hokfelt, T.; Broberger, C.; Xu, Z.Q.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides - an overview. Neuropharmacology, 2000, 39(8), 1337-1356.
8. Bean, A.J.; Zhang, X.; Hokfelt, T. Peptide secretion: What do we know? FASEB J, 1994, 8(9), 630-638.
9. Hokfelt, T.; Bean, A.; Ceccatelli, S.; Dagerlind, A.; Elde, R.P.; Goldstein, M.; Meister, B.; Melander, T.; Nicholas, A.P.; Pelto-Huikko, M.; et al. Neuropeptides and classical transmitters. Localization and interaction. Arzneimittelforschung, 1992, 42(2A), 196-201.
10. Hokfelt, T.; Millhorn, D.; Seroogy, K.; Tsuruo, Y.; Ceccatelli, S.; Lindh, B.; Meister, B.; Melander, T.; Schalling, M.; Bartfai, T.; et al. Coexistence of peptides with classical neurotransmitters. Experientia, 1987, 43(7), 768-780.
11. Fredholm, B.B.; Hokfelt, T.; Milligan, G. G-protein-coupled receptors: An update. Acta Physiol (Oxf), 2007, 190(1), 3-7.
12. Jacoby, E.; Bouhelal, R.; Gerspacher, M.; Seuwen, K. The 7 tm gprotein- coupled receptor target family. ChemMedChem, 2006, 1(8), 761-782.
13. van den Pol, A.N. Neuropeptide transmission in brain circuits. Neuron, 2012, 76(1), 98-115.
14. Werner, F.M.; Covenas, R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: A focus on antiepileptic drugs. Curr Med Chem, 2011, 18(32), 4933-4948.
15. Wasterlain, C.G.; Liu, H.; Mazarati, A.M.; Baldwin, R.A.; Shirasaka, Y.; Katsumori, H.; Thompson, K.W.; Sankar, R.; Pereira de Vasconselos, A.; Nehlig, A. Self-sustaining status epilepticus: A condition maintained by potentiation of glutamate receptors and by plastic changes in substance p and other peptide neuromodulators. Epilepsia, 2000, 41 Suppl 6, S134-143.
16. McGonigle, P. Peptide therapeutics for cns indications. Biochem Pharmacol, 2012, 83(5), 559-566.
17. Pitkanen, A. New pharmacotherapy for epilepsy. IDrugs, 2004, 7(5), 471-477.
18. Boison, D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol, 2007, 5(2), 115-125.
19. Riban, V.; Fitzsimons, H.L.; During, M.J. Gene therapy in epilepsy. Epilepsia, 2009, 50(1), 24-32.
20. Weinberg, M.S.; McCown, T.J. Current prospects and challenges for epilepsy gene therapy. Exp Neurol, 2011.
21. McCown, T.J. The future of epilepsy treatment: Focus on adenoassociated virus vector gene therapy. Drug News Perspect, 2010, 23(5), 281-286.
22. Freund, T.F.; Buzsaki, G. Interneurons of the hippocampus. Hippocampus, 1996, 6(4), 347-470.
23. Somogyi, P.; Klausberger, T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol, 2005, 562(Pt 1), 9-26.
24. de Lanerolle, N.C.; Lee, T.S.; Spencer, D.D. Histopathology of human epilepsy. In: Jasper's basic mechanisms of the epilepsies; Noebels, J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V., Eds.; Bethesda (MD), 2012.
25. Vitko, I.; Chen, Y.; Arias, J.M.; Shen, Y.; Wu, X.R.; Perez-Reyes, E. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of cacna1h, a t-type calcium channel. J Neurosci, 2005, 25(19), 4844-4855.
26. van Raay, L.; Jovanovska, V.; Morris, M.J.; O'Brien, T.J. Focal administration of neuropeptide y into the s2 somatosensory cortex maximally suppresses absence seizures in a genetic rat model. Epilepsia, 2012, 53(3), 477-484.
27. Morris, M.J.; Gannan, E.; Stroud, L.M.; Beck-Sickinger, A.G.; O'Brien, T.J. Neuropeptide y suppresses absence seizures in a genetic rat model primarily through effects on y receptors. Eur J Neurosci, 2007, 25(4), 1136-1143.
28. Efendic, S.; Hokfelt, T.; Luft, R. Somatostatin. Adv Metab Disord, 1978, 9, 367-424.
29. Viollet, C.; Lepousez, G.; Loudes, C.; Videau, C.; Simon, A.; Epelbaum, J. Somatostatinergic systems in brain: Networks and functions. Mol Cell Endocrinol, 2008, 286(1-2), 75-87.
30. Marti, M.; Bregola, G.; Morari, M.; Gemignani, A.; Simonato, M. Somatostatin release in the hippocampus in the kindling model of epilepsy: A microdialysis study. J Neurochem, 2000, 74(6), 2497-2503.
31. Hashimoto, T.; Obata, K. Induction of somatostatin by kainic acid in pyramidal and granule cells of the rat hippocampus. Neurosci Res, 1991, 12(4), 514-527.
32. Kobayashi, M.; Buckmaster, P.S. Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J Neurosci, 2003, 23(6), 2440-2452.
33. Tallent, M.K.; Qiu, C. Somatostatin: An endogenous antiepileptic. Mol Cell Endocrinol, 2008, 286(1-2), 96-103.
34. Monno, A.; Rizzi, M.; Samanin, R.; Vezzani, A. Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats. Brain Res, 1993, 602(1), 148-152.
35. Csaba, Z.; Dournaud, P. Cellular biology of somatostatin receptors. Neuropeptides, 2001, 35(1), 1-23.
36. Qiu, C.; Zeyda, T.; Johnson, B.; Hochgeschwender, U.; de Lecea, L.; Tallent, M.K. Somatostatin receptor subtype 4 couples to the mcurrent to regulate seizures. J Neurosci, 2008, 28(14), 3567-3576.
37. De Bundel, D.; Aourz, N.; Kiagiadaki, F.; Clinckers, R.; Hoyer, D.; Kastellakis, A.; Michotte, Y.; Thermos, K.; Smolders, I. Hippocampal sst(1) receptors are autoreceptors and do not affect seizures in rats. Neuroreport, 2010, 21(4), 254-258.
38. Rohrer, S.P.; Birzin, E.T.; Mosley, R.T.; Berk, S.C.; Hutchins, S.M.; Shen, D.M.; Xiong, Y.; Hayes, E.C.; Parmar, R.M.; Foor, F.; Mitra, S.W.; Degrado, S.J.; Shu, M.; Klopp, J.M.; Cai, S.J.; Blake, A.; Chan, W.W.; Pasternak, A.; Yang, L.; Patchett, A.A.; Smith, R.G.; Chapman, K.T.; Schaeffer, J.M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science, 1998, 282(5389), 737-740.
39. Rohrer, S.P.; Schaeffer, J.M. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol Paris, 2000, 94(3-4), 211-215.
40. Hoyer, D.; Nunn, C.; Hannon, J.; Schoeffter, P.; Feuerbach, D.; Schuepbach, E.; Langenegger, D.; Bouhelal, R.; Hurth, K.; Neumann, P.; Troxler, T.; Pfaeffli, P. Sra880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci Lett, 2004, 361(1-3), 132-135.
41. Feniuk, W.; Jarvie, E.; Luo, J.; Humphrey, P.P. Selective somatostatin sst(2) receptor blockade with the novel cyclic octapeptide, cyn-154806. Neuropharmacology, 2000, 39(8), 1443-1450.
42. Reubi, J.C.; Schaer, J.C.; Wenger, S.; Hoeger, C.; Erchegyi, J.; Waser, B.; Rivier, J. Sst3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci U S A, 2000, 97(25), 13973-13978.
43. Moneta, D.; Richichi, C.; Aliprandi, M.; Dournaud, P.; Dutar, P.; Billard, J.M.; Carlo, A.S.; Viollet, C.; Hannon, J.P.; Fehlmann, D.; Nunn, C.; Hoyer, D.; Epelbaum, J.; Vezzani, A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur J Neurosci, 2002, 16(5), 843-849.
44. Aourz, N.; De Bundel, D.; Stragier, B.; Clinckers, R.; Portelli, J.; Michotte, Y.; Smolders, I. Rat hippocampal somatostatin sst3 and sst4 receptors mediate anticonvulsive effects in vivo: Indications of functional interactions with sst2 receptors. Neuropharmacology, 2011, 61(8), 1327-1333.
45. Pedrazzini, T.; Pralong, F.; Grouzmann, E. Neuropeptide y: The universal soldier. Cell Mol Life Sci, 2003, 60(2), 350-377.
46. Colmers, W.F.; Lukowiak, K.; Pittman, Q.J. Neuropeptide y action in the rat hippocampal slice: Site and mechanism of presynaptic inhibition. J Neurosci, 1988, 8(10), 3827-3837.
47. Marksteiner, J.; Sperk, G.; Maas, D. Differential increases in brain levels of neuropeptide y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch Pharmacol, 1989, 339(1-2), 173-177.
48. Sloviter, R.S. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: The "dormant basket cell" hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus, 1991, 1(1), 41-66.
49. Lagrange, A.H. Valproate enhances neuropeptide y expression: Modulating the modulators. Epilepsy Curr, 2007, 7(4), 107-109.
50. Woldbye, D.P.; Kokaia, M. Neuropeptide y and seizures: Effects of exogenously applied ligands. Neuropeptides, 2004, 38(4), 253-260.
51. Colmers, W.F.; El Bahh, B. Neuropeptide y and epilepsy. Epilepsy Curr, 2003, 3(2), 53-58.
52. Vezzani, A.; Moneta, D.; Mule, F.; Ravizza, T.; Gobbi, M.; French-Mullen, J. Plastic changes in neuropeptide y receptor subtypes in experimental models of limbic seizures. Epilepsia, 2000, 41 Suppl 6, S115-121.
53. Husum, H.; Gruber, S.H.; Bolwig, T.G.; Mathe, A.A. Extracellular levels of npy in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive y1 receptor blockade. Neuropeptides, 2002, 36(5), 363-369.
54. Erickson, J.C.; Clegg, K.E.; Palmiter, R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide y. Nature, 1996, 381(6581), 415-421.
55. Vezzani, A.; Michalkiewicz, M.; Michalkiewicz, T.; Moneta, D.; Ravizza, T.; Richichi, C.; Aliprandi, M.; Mule, F.; Pirona, L.; Gobbi, M.; Schwarzer, C.; Sperk, G. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide y. Neuroscience, 2002, 110(2), 237-243.
56. Richichi, C.; Lin, E.J.; Stefanin, D.; Colella, D.; Ravizza, T.; Grignaschi, G.; Veglianese, P.; Sperk, G.; During, M.J.; Vezzani, A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide y expression in the rat hippocampus. J Neurosci, 2004, 24(12), 3051-3059.
57. Eaton, K.; Sallee, F.R.; Sah, R. Relevance of neuropeptide y (npy) in psychiatry. Curr Top Med Chem, 2007, 7(17), 1645-1659.
58. Walther, C.; Morl, K.; Beck-Sickinger, A.G. Neuropeptide y receptors: Ligand binding and trafficking suggest novel approaches in drug development. J Pept Sci, 2011, 17(4), 233-246.
59. Cabrele, C.; Beck-Sickinger, A.G. Molecular characterization of the ligand-receptor interaction of the neuropeptide y family. J Pept Sci, 2000, 6(3), 97-122.
60. Olesen, M.V.; Christiansen, S.H.; Gotzsche, C.R.; Nikitidou, L.; Kokaia, M.; Woldbye, D.P. Neuropeptide y y1 receptor hippocampal overexpression via viral vectors is associated with modest anxiolytic-like and proconvulsant effects in mice. J Neurosci Res, 2012, 90(2), 498-507.
61. Gotzsche, C.R.; Nikitidou, L.; Sorensen, A.T.; Olesen, M.V.; Sorensen, G.; Christiansen, S.H.; Angehagen, M.; Woldbye, D.P.; Kokaia, M. Combined gene overexpression of neuropeptide y and its receptor y5 in the hippocampus suppresses seizures. Neurobiol Dis, 2012, 45(1), 288-296.
62. Marsh, D.J.; Baraban, S.C.; Hollopeter, G.; Palmiter, R.D. Role of the y5 neuropeptide y receptor in limbic seizures. Proc Natl Acad Sci U S A, 1999, 96(23), 13518-13523.
63. Lin, E.J.; Young, D.; Baer, K.; Herzog, H.; During, M.J. Differential actions of npy on seizure modulation via y1 and y2 receptors: Evidence from receptor knockout mice. Epilepsia, 2006, 47(4), 773-780.
64. Meurs, A.; Clinckers, R.; Ebinger, G.; Michotte, Y.; Smolders, I. Clinical potential of neuropeptide y receptor ligands in the treatment of epilepsy. Curr Top Med Chem, 2007, 7(17), 1660-1674.
65. Balasubramaniam, A.; Sheriff, S.; Zhai, W.; Chance, W.T. Bis(31/31')[[cys(31), nva(34)]npy(27-36)-nh(2)]: A neuropeptide y (npy) y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides, 2002, 23(8), 1485-1490.
66. Aiglstorfer, I.; Hendrich, I.; Moser, C.; Bernhardt, G.; Dove, S.; Buschauer, A. Structure-activity relationships of neuropeptide y y1 receptor antagonists related to bibp 3226. Bioorg Med Chem Lett, 2000, 10(14), 1597-1600.
67. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Konig, B. Modular synthesis of non-peptidic bivalent npy y1 receptor antagonists. Bioorg Med Chem, 2008, 16(22), 9858-9866.
68. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Konig, B. N(g)-acyl-argininamides as npy y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity. Bioorg Med Chem, 2010, 18(17), 6292-6304.
69. Mazarati, A.M.; Halaszi, E.; Telegdy, G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res, 1992, 589(1), 164-166.
70. Kokaia, M.; Holmberg, K.; Nanobashvili, A.; Xu, Z.Q.; Kokaia, Z.; Lendahl, U.; Hilke, S.; Theodorsson, E.; Kahl, U.; Bartfai, T.; Lindvall, O.; Hokfelt, T. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci U S A, 2001, 98(24), 14006-14011.
71. Melander, T.; Staines, W.A.; Rokaeus, A. Galanin-like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs. Neuroscience, 1986, 19(1), 223-240.
72. Xu, Z.Q.; Shi, T.J.; Hokfelt, T. Galanin/gmap- and npy-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-r1 and -r2 receptors. J Comp Neurol, 1998, 392(2), 227-251.
73. Arabadzisz, D.; Antal, K.; Parpan, F.; Emri, Z.; Fritschy, J.M. Epileptogenesis and chronic seizures in a mouse model of temporal lobe epilepsy are associated with distinct eeg patterns and selective neurochemical alterations in the contralateral hippocampus. Exp Neurol, 2005, 194(1), 76-90.
74. Mazarati, A.M.; Baldwin, R.A.; Shinmei, S.; Sankar, R. In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: Implication for limbic seizures. J Neurochem, 2005, 95(5), 1495-1503.
75. Branchek, T.A.; Smith, K.E.; Gerald, C.; Walker, M.W. Galanin receptor subtypes. Trends Pharmacol Sci, 2000, 21(3), 109-117.
76. Mazarati, A.; Lu, X.; Shinmei, S.; Badie-Mahdavi, H.; Bartfai, T. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (galr1) knockout mice. Neuroscience, 2004, 128(2), 431-441.
77. Mazarati, A.; Lu, X.; Kilk, K.; Langel, U.; Wasterlain, C.; Bartfai, T. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci, 2004, 19(12), 3235-3244.
78. Runesson, J.; Saar, I.; Lundstrom, L.; Jarv, J.; Langel, U. A novel galr2-specific peptide agonist. Neuropeptides, 2009, 43(3), 187-192.
79. Bulaj, G.; Green, B.R.; Lee, H.K.; Robertson, C.R.; White, K.; Zhang, L.; Sochanska, M.; Flynn, S.P.; Scholl, E.A.; Pruess, T.H.; Smith, M.D.; White, H.S. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem, 2008, 51(24), 8038-8047.
80. Lerner, J.T.; Sankar, R.; Mazarati, A.M. Galanin and epilepsy. Cell Mol Life Sci, 2008, 65(12), 1864-1871.
81. Ceide, S.C.; Trembleau, L.; Haberhauer, G.; Somogyi, L.; Lu, X.; Bartfai, T.; Rebek, J., Jr. Synthesis of galmic: A nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A, 2004, 101(48), 16727-16732.
82. Bartfai, T.; Lu, X.; Badie-Mahdavi, H.; Barr, A.M.; Mazarati, A.; Hua, X.Y.; Yaksh, T.; Haberhauer, G.; Ceide, S.C.; Trembleau, L.; Somogyi, L.; Krock, L.; Rebek, J., Jr. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forcedswim tests. Proc Natl Acad Sci U S A, 2004, 101(28), 10470-10475.
83. Hoyer, D. Neuropeptide receptor positive allosteric modulation in epilepsy: Galanin modulation revealed. Proc Natl Acad Sci U S A, 2010, 107(34), 14943-14944.
84. Lu, X.; Roberts, E.; Xia, F.; Sanchez-Alavez, M.; Liu, T.; Baldwin, R.; Wu, S.; Chang, J.; Wasterlain, C.G.; Bartfai, T. Galr2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc Natl Acad Sci U S A, 2010, 107(34), 15229-15234.
85. Sagi, V.N.; Liu, T.; Lu, X.; Bartfai, T.; Roberts, E. Synthesis and biological evaluation of novel pyrimidine derivatives as submicromolar affinity ligands of galr2. Bioorg Med Chem Lett, 2011, 21(23), 7210-7215.
86. Holden, J.E.; Jeong, Y.; Forrest, J.M. The endogenous opioid system and clinical pain management. AACN Clin Issues, 2005, 16(3), 291-301.
87. LaForge, K.S.; Nyberg, F.; Kreek, M.J. Primary structure of guinea pig preprodynorphin and preproenkephalin mrnas: Multiple transcription initiation sites for preprodynorphin. Brain Res Bull, 2004, 63(2), 119-126.
88. Feng, Y.; He, X.; Yang, Y.; Chao, D.; Lazarus, L.H.; Xia, Y. Current research on opioid receptor function. Curr Drug Targets, 2012, 13(2), 230-246.
89. Drake, C.T.; Chavkin, C.; Milner, T.A. Opioid systems in the dentate gyrus. Prog Brain Res, 2007, 163, 245-263.
90. Hong, J.S.; McGinty, J.F.; Grimes, L.; Kanamatsu, T.; Obie, J.; Mitchell, C.L. Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizurerelated behaviors. NIDA Res Monogr, 1988, 82, 48-66.
91. Asai, M.; Matamoros-Trejo, G.; Linares, G. Long-term pharmacological kindling increases in vitro release of ir-met and irleu- enkephalin from amygdala. Comp Biochem Physiol A Mol Integr Physiol, 1998, 120(2), 269-275.
92. Przewlocki, R.; Kaminska, B.; Lukasiuk, K.; Nowicka, D.Z.; Przewlocka, B.; Kaczmarek, L.; Lason, W. Seizure related changes in the regulation of opioid genes and transcription factors in the dentate gyrus of rat hippocampus. Neuroscience, 1995, 68(1), 73-81.
93. Harrison, M.B.; Shumate, M.D.; Lothman, E.W. Opioid peptide expression in models of chronic temporal lobe epilepsy. Neuroscience, 1995, 65(3), 785-795.
94. Fetissov, S.O.; Jacoby, A.S.; Brumovsky, P.R.; Shine, J.; Iismaa, T.P.; Hokfelt, T. Altered hippocampal expression of neuropeptides in seizure-prone galr1 knockout mice. Epilepsia, 2003, 44(8), 1022-1033.
95. Rocha, L.; Cano, A.; Cruz, C.; Omana-Zapata, I.; Villalobos, R.; Maidment, N.T. Opioid peptide systems following a subconvulsant dose of pentylenetetrazol in rats. Epilepsy Res, 1999, 37(2), 141-150.
96. Bing, G.; Wilson, B.; Hudson, P.; Jin, L.; Feng, Z.; Zhang, W.; Bing, R.; Hong, J.S. A single dose of kainic acid elevates the levels of enkephalins and activator protein-1 transcription factors in the hippocampus for up to 1 year. Proc Natl Acad Sci U S A, 1997, 94(17), 9422-9427.
97. Rees, H.; Ang, L.C.; Shul, D.D.; George, D.H.; Begley, H.; McConnell, T. Increase in enkephalin-like immunoreactivity in hippocampi of adults with generalized epilepsy. Brain Res, 1994, 652(1), 113-119.
98. Pretel, S.; Applegate, C.D.; Piekut, D.T. Seizure-induced activation of enkephalin- and somatostatin-synthesizing neurons. Peptides, 1995, 16(5), 951-957.
99. Mazarati, A.; Liu, H.; Wasterlain, C. Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience, 1999, 89(1), 167-173.
100. Pirker, S.; Gasser, E.; Czech, T.; Baumgartner, C.; Schuh, E.; Feucht, M.; Novak, K.; Zimprich, F.; Sperk, G. Dynamic upregulation of prodynorphin transcription in temporal lobe epilepsy. Hippocampus, 2009, 19(11), 1051-1054.
101. Tortella, F.C. Endogenous opioid peptides and epilepsy: Quieting the seizing brain? Trends Pharmacol Sci, 1988, 9(10), 366-372.
102. Comer, S.D.; Hoenicke, E.M.; Sable, A.I.; McNutt, R.W.; Chang, K.J.; De Costa, B.R.; Mosberg, H.I.; Woods, J.H. Convulsive effects of systemic administration of the delta opioid agonist bw373u86 in mice. J Pharmacol Exp Ther, 1993, 267(2), 888-895.
103. Cain, D.P.; Boon, F.; Corcoran, M.E. Involvement of multiple opiate receptors in opioid kindling. Brain Res, 1990, 517(1-2), 236-244.
104. Tortella, F.C.; Robles, L.; Mosberg, H.I. Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J Pharmacol Exp Ther, 1987, 240(2), 571-577.
105. Haffmans, J.; Dzoljic, M.R. Differential epileptogenic potentials of selective mu and delta opiate receptor agonists. J Neural Transm, 1983, 57(1-2), 1-11.
106. Lason, W.; Simpson, J.N.; McGinty, J.F. Mu but not delta opioid receptor stimulation intensifies kainic acid-induced neurotoxicity in rat hippocampus. Neuropeptides, 1988, 12(2), 89-94.
107. Tortella, F.C.; Robles, L.E.; Holaday, J.W.; Cowan, A. Ici 154,129, a delta-opioid receptor antagonist raises seizure threshold in rats. Eur J Pharmacol, 1984, 97(1-2), 141-144.
108. Grecksch, G.; Becker, A.; Schroeder, H.; Hollt, V. Involvement of delta-opioid receptors in pentylenetetrazol kindling development and kindling-related processes in rats. Naunyn Schmiedebergs Arch Pharmacol, 1999, 360(2), 151-156.
109. Schroeder, H.; Becker, A.; Grecksch, G.; Schroeder, U.; Hoellt, V. The effect of pentylenetetrazol kindling on synaptic mechanisms of interacting glutamatergic and opioid system in the hippocampus of rats. Brain Res, 1998, 811(1-2), 40-46.
110. Mitchell, C.L.; Barnes, M.I.; Hudson, P.M.; Hong, J.S. Opioid mu and delta receptor antagonists reduce wet dog shaking elicited by perforant path stimulation. Pharmacol Biochem Behav, 1991, 38(4), 801-805.
111. Jackson, H.C.; Nutt, D.J. Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice. Psychopharmacology (Berl), 1991, 103(3), 380-383.
112. Yajima, Y.; Narita, M.; Takahashi-Nakano, Y.; Misawa, M.; Nagase, H.; Mizoguchi, H.; Tseng, L.F.; Suzuki, T. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res, 2000, 862(1-2), 120-126.
113. Tortella, F.C.; Robles, L.; Holaday, J.W. U50,488, a highly selective kappa opioid: Anticonvulsant profile in rats. J Pharmacol Exp Ther, 1986, 237(1), 49-53.
114. Saboory, E.; Derchansky, M.; Ismaili, M.; Jahromi, S.S.; Brull, R.; Carlen, P.L.; El Beheiry, H. Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg, 2007, 105(6), 1729-1735, table of contents.
115. Shafaroodi, H.; Baradaran, N.; Moezi, L.; Dehpour, S.; Kabiri, T.; Dehpour, A.R. Morphine sensitization in the pentylenetetrazoleinduced clonic seizure threshold in mice: Role of nitric oxide and mu receptors. Epilepsy Behav, 2011, 20(4), 602-606.
116. Simmons, M.L.; Chavkin, C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol, 1996, 39, 145-196.
117. Solbrig, M.V.; Adrian, R.; Baratta, J.; Lauterborn, J.C.; Koob, G.F. Kappa opioid control of seizures produced by a virus in an animal model. Brain, 2006, 129(Pt 3), 642-654.
118. Solbrig, M.V.; Koob, G.F. Epilepsy, cns viral injury and dynorphin. Trends Pharmacol Sci, 2004, 25(2), 98-104.
119. Przewlocka, B.; Lason, W.; Machelska, H.; van Luijtelaar, G.; Coenen, A.; Przewlocki, R. Kappa opioid receptor agonists suppress absence seizures in wag/rij rats. Neurosci Lett, 1995, 186(2-3), 131-134.
120. Mizuno, T.; Kimura, F. Medial septal injection of naloxone elevates acetylcholine release in the hippocampus and induces behavioral seizures in rats. Brain Res, 1996, 713(1-2), 1-7.
121. Loacker, S.; Sayyah, M.; Wittmann, W.; Herzog, H.; Schwarzer, C. Endogenous dynorphin in epileptogenesis and epilepsy: Anticonvulsant net effect via kappa opioid receptors. Brain, 2007, 130(Pt 4), 1017-1028.
122. Schunk, E.; Aigner, C.; Stefanova, N.; Wenning, G.; Herzog, H.; Schwarzer, C. Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection. Hippocampus, 2011, 21(9), 1010-1020.
123. Stogmann, E.; Zimprich, A.; Baumgartner, C.; Aull-Watschinger, S.; Hollt, V.; Zimprich, F. A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann Neurol, 2002, 51(2), 260-263.
124. Dietis, N.; Rowbotham, D.J.; Lambert, D.G. Opioid receptor subtypes: Fact or artifact? Br J Anaesth, 2011, 107(1), 8-18.
125. Jordan, B.; Devi, L.A. Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth, 1998, 81(1), 12-19.
126. Kaczor, A.; Matosiuk, D. Non-peptide opioid receptor ligands - recent advances. Part i - agonists. Curr Med Chem, 2002, 9(17), 1567-1589.
127. Kaminski, R.M.; Witkin, J.M.; Shippenberg, T.S. Pharmacological and genetic manipulation of kappa opioid receptors: Effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology, 2007, 52(3), 895-903.
128. Manocha, A.; Mediratta, P.K.; Sharma, K.K. Studies on the anticonvulsant effect of u50488h on maximal electroshock seizure in mice. Pharmacol Biochem Behav, 2003, 76(1), 111-117.
129. Manocha, A.; Sharma, K.K.; Mediratta, P.K. Possible mechanism involved in the anticonvulsant action of butorphanol in mice. Pharmacol Biochem Behav, 2003, 74(2), 343-350.
130. Bausch, S.B.; Esteb, T.M.; Terman, G.W.; Chavkin, C. Administered and endogenously released kappa opioids decrease pilocarpine-induced seizures and seizure-induced histopathology. J Pharmacol Exp Ther, 1998, 284(3), 1147-1155.
131. Frey, H.H. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and mr 2266. Pharmacol Toxicol, 1988, 62(3), 150-154.
132. Kaczor, A.; Matosiuk, D. Non-peptide opioid receptor ligands - recent advances. Part ii - antagonists. Curr Med Chem, 2002, 9(17), 1591-1603.
133. Fichna, J.; Socala, K.; Nieoczym, D.; Gach, K.; Perlikowska, R.; Janecka, A.; Wlaz, P. The mu-opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 40, 126-131.
134. Liu, H.; Gao, H.M.; Zhang, W.Q.; Tang, Y.Y.; Song, H.S. Effects of chronic administration of pl017 and beta-funaltrexamine hydrochloride on susceptibility of kainic acid-induced seizures in rats. Sheng Li Xue Bao, 2004, 56(1), 101-106.
135. Lee, P.H.; Obie, J.; Hong, J.S. Opioids induce convulsions and wet dog shakes in rats: Mediation by hippocampal mu, but not delta or kappa opioid receptors. J Neurosci, 1989, 9(2), 692-697.
136. Jackson, H.C.; Nutt, D.J. Investigation of the involvement of opioid receptors in the action of anticonvulsants. Psychopharmacology (Berl), 1993, 111(4), 486-490.
137. Harrison, S.; Geppetti, P. Substance p. Int J Biochem Cell Biol, 2001, 33(6), 555-576.
138. Borhegyi, Z.; Leranth, C. Substance p innervation of the rat hippocampal formation. J Comp Neurol, 1997, 384(1), 41-58.
139. Roberts, G.W.; Woodhams, P.L.; Polak, J.M.; Crow, T.J. Distribution of neuropeptides in the limbic system of the rat: The hippocampus. Neuroscience, 1984, 11(1), 35-77.
140. Lotstra, F.; Mailleux, P.; Vanderhaeghen, J.J. Substance p neurons in the human hippocampus: An immunohistochemical analysis in the infant and adult. J Chem Neuroanat, 1988, 1(2), 111-123.
141. Borhegyi, Z.; Leranth, C. Distinct substance p- and calretinincontaining projections from the supramammillary area to the hippocampus in rats; a species difference between rats and monkeys. Exp Brain Res, 1997, 115(2), 369-374.
142. Peterson, G.M.; Shurlow, C.L. Morphological evidence for a substance p projection from medial septum to hippocampus. Peptides, 1992, 13(3), 509-517.
143. Liu, H.; Sankar, R.; Shin, D.H.; Mazarati, A.M.; Wasterlain, C.G. Patterns of status epilepticus-induced substance p expression during development. Neuroscience, 2000, 101(2), 297-304.
144. Liu, H.; Cao, Y.; Basbaum, A.I.; Mazarati, A.M.; Sankar, R.; Wasterlain, C.G. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin a gene. Proc Natl Acad Sci U S A, 1999, 96(21), 12096-12101.
145. Robinson, P.; Garza, A.; Weinstock, J.; Serpa, J.A.; Goodman, J.C.; Eckols, K.T.; Firozgary, B.; Tweardy, D.J. Substance p causes seizures in neurocysticercosis. PLoS Pathog, 2012, 8(2), e1002489.
146. Ogier, R.; Raggenbass, M. Action of tachykinins in the rat hippocampus: Modulation of inhibitory synaptic transmission. Eur J Neurosci, 2003, 17(12), 2639-2647.
147. Stacey, A.E.; Woodhall, G.L.; Jones, R.S. Neurokinin-receptormediated depolarization of cortical neurons elicits an increase in glutamate release at excitatory synapses. Eur J Neurosci, 2002, 16(10), 1896-1906.
148. Ogier, R.; Wrobel, L.J.; Raggenbass, M. Action of tachykinins in the hippocampus: Facilitation of inhibitory drive to gabaergic interneurons. Neuroscience, 2008, 156(3), 527-536.
149. Roush, E.D.; Kwatra, M.M. Human substance p receptor expressed in chinese hamster ovary cells directly activates g(alpha q/11), g(alpha s), g(alpha o). FEBS Lett, 1998, 428(3), 291-294.
150. Takeda, Y.; Blount, P.; Sachais, B.S.; Hershey, A.D.; Raddatz, R.; Krause, J.E. Ligand binding kinetics of substance p and neurokinin a receptors stably expressed in chinese hamster ovary cells and evidence for differential stimulation of inositol 1,4,5-trisphosphate and cyclic amp second messenger responses. J Neurochem, 1992, 59(2), 740-745.
151. Acsady, L.; Katona, I.; Gulyas, A.I.; Shigemoto, R.; Freund, T.F. Immunostaining for substance p receptor labels gabaergic cells with distinct termination patterns in the hippocampus. J Comp Neurol, 1997, 378(3), 320-336.
152. Sloviter, R.S.; Ali-Akbarian, L.; Horvath, K.D.; Menkens, K.A. Substance p receptor expression by inhibitory interneurons of the rat hippocampus: Enhanced detection using improved immunocytochemical methods for the preservation and colocalization of gaba and other neuronal markers. J Comp Neurol, 2001, 430(3), 283-305.
153. Toth, K.; Wittner, L.; Urban, Z.; Doyle, W.K.; Buzsaki, G.; Shigemoto, R.; Freund, T.F.; Magloczky, Z. Morphology and synaptic input of substance p receptor-immunoreactive interneurons in control and epileptic human hippocampus. Neuroscience, 2007, 144(2), 495-508.
154. Magloczky, Z. Sprouting in human temporal lobe epilepsy: Excitatory pathways and axons of interneurons. Epilepsy Res, 2010, 89(1), 52-59.
155. Danfors, T.; Ahs, F.; Appel, L.; Linnman, C.; Fredrikson, M.; Furmark, T.; Kumlien, E. Increased neurokinin-1 receptor availability in temporal lobe epilepsy: A positron emission tomography study using [(11)c]gr205171. Epilepsy Res, 2011, 97(1-2), 183-189.
156. Rosen, T.J.; Coffman, K.J.; McLean, S.; Crawford, R.T.; Bryce, D.K.; Gohda, Y.; Tsuchiya, M.; Nagahisa, A.; Nakane, M.; Lowe, J.A., 3rd Synthesis and structure-activity relationships of cp- 122,721, a second-generation nk-1 receptor antagonist. Bioorg Med Chem Lett, 1998, 8(3), 281-284.
157. Syvanen, S.; Eriksson, J.; Genchel, T.; Lindhe, O.; Antoni, G.; Langstrom, B. Synthesis of two potential nk1-receptor ligands using [1-11c]ethyl iodide and [1-11c]propyl iodide and initial petimaging. BMC Med Imaging, 2007, 7, 6.
158. Wahlestedt, C. Reward for persistence in substance p research. Science, 1998, 281(5383), 1624-1625.
159. dos Santos, L.V.; Souza, F.H.; Brunetto, A.T.; Sasse, A.D.; da Silveira Nogueira Lima, J.P. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review. J Natl Cancer Inst, 2012, 104(17), 1280-1292.
160. Zachrisson, O.; Lindefors, N.; Brene, S. A tachykinin nk1 receptor antagonist, cp-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res, 1998, 60(2), 291-295.
161. Kalinichev, M.; Bradford, A.; Bison, S.; Lucas, A.; Sartori, I.; Garbati, N.; Andreetta, F.; Bate, S.; Austin, N.E.; Jones, D.N.; Read, K.D.; Alvaro, G.; Large, C.H. Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an nk1- receptor antagonist in the rat. Epilepsia, 2010, 51(8), 1543-1551.
162. Alvaro, G.; Di Fabio, R. Neurokinin 1 receptor antagonists - current prospects. Curr Opin Drug Discov Devel, 2007, 10(5), 613-621.
163. Dockray, G.J. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes, 2012, 19(1), 8-12.
164. Lee, S.Y.; Soltesz, I. Cholecystokinin: A multi-functional molecular switch of neuronal circuits. Dev Neurobiol, 2011, 71(1), 83-91.
165. Wyeth, M.S.; Zhang, N.; Houser, C.R. Increased cholecystokinin labeling
166. Kadar, T.; Pesti, A.; Penke, B.; Telegdy, G. Inhibition of seizures induced by picrotoxin and electroshock by cholecystokinin octapeptides and their fragments in rats after intracerebroventricular administration. Neuropharmacology, 1984, 23(8), 955-961.
167. Zetler, G. Anticonvulsant effects of caerulein, cholecystokinin octapeptide (cck-8) and diazepam against seizures produced in mice by harman, thiosemicarbazide and isoniazid. Neurosci Lett, 1981, 24(2), 175-180.
168. Ferraro, G.; Sardo, P. Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat. Epilepsia, 2009, 50(4), 721-730.
169. Tirassa, P.; Costa, N.; Aloe, L. Cck-8 prevents the development of kindling and regulates the gaba and npy expression in the hippocampus of pentylenetetrazole (ptz)-treated adult rats. Neuropharmacology, 2005, 48(5), 732-742.
170. Deng, P.Y.; Xiao, Z.; Jha, A.; Ramonet, D.; Matsui, T.; Leitges, M.; Shin, H.S.; Porter, J.E.; Geiger, J.D.; Lei, S. Cholecystokinin facilitates glutamate release by increasing the number of readily releasable vesicles and releasing probability. J Neurosci, 2010, 30(15), 5136-5148.
171. Shinohara, S.; Kawasaki, K. Electrophysiological changes in rat hippocampal pyramidal neurons produced by cholecystokinin octapeptide. Neuroscience, 1997, 78(4), 1005-1016.
172. Dufresne, M.; Seva, C.; Fourmy, D. Cholecystokinin and gastrin receptors. Physiol Rev, 2006, 86(3), 805-847.
173. Noble, F.; Roques, B.P. Cck-b receptor: Chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol, 1999, 58(4), 349-379.
174. Kalindjian, S.B.; McDonald, I.M. Strategies for the design of nonpeptide cck2 receptor agonist and antagonist ligand. Curr Top Med Chem, 2007, 7(12), 1195-1204.
175. Harro, J. Cck and npy as anti-anxiety treatment targets: Promises, pitfalls, and strategies. Amino Acids, 2006, 31(3), 215-230.
176. Eser, D.; Leicht, G.; Lutz, J.; Wenninger, S.; Kirsch, V.; Schule, C.; Karch, S.; Baghai, T.; Pogarell, O.; Born, C.; Rupprecht, R.; Mulert, C. Functional neuroanatomy of cck-4-induced panic attacks in healthy volunteers. Hum Brain Mapp, 2009, 30(2), 511-522.
177. Wilson, J.; Little, H.J. Cck(b) antagonists protect against some aspects of the ethanol withdrawal syndrome. Pharmacol Biochem Behav, 1998, 59(4), 967-973.
178. Gozes, I.; Brenneman, D.E. Vip: Molecular biology and neurobiological function. Mol Neurobiol, 1989, 3(4), 201-236.
179. Papp, E.C.; Hajos, N.; Acsady, L.; Freund, T.F. Medial septal and median raphe innervation of vasoactive intestinal polypeptidecontaining interneurons in the hippocampus. Neuroscience, 1999, 90(2), 369-382.
180. Hajos, N.; Acsady, L.; Freund, T.F. Target selectivity and neurochemical characteristics of vip-immunoreactive interneurons in the rat dentate gyrus. Eur J Neurosci, 1996, 8(7), 1415-1431.
181. Romualdi, P.; Lesa, G.; Donatini, A.; Balboni, G.; Tomatis, R.; Ferri, S. Alterations in vasoactive intestinal polypeptide-related peptides after pentylenetetrazole-induced seizures in rat brain. Eur J Pharmacol, 1992, 229(2-3), 149-153.
182. Cunha-Reis, D.; Fontinha, B.M.; Ribeiro, J.A.; Sebastiao, A.M. Tonic adenosine a1 and a2a receptor activation is required for the excitatory action of vip on synaptic transmission in the ca1 area of the hippocampus. Neuropharmacology, 2007, 52(2), 313-320.
183. Yang, K.; Lei, G.; Jackson, M.F.; Macdonald, J.F. The involvement of pacap/vip system in the synaptic transmission in the hippocampus. J Mol Neurosci, 2010, 42(3), 319-326.
184. Koh, S.W.; Cheng, J.; Dodson, R.M.; Ku, C.Y.; Abbondandolo, C.J. Vip down-regulates the inflammatory potential and promotes survival of dying (neural crest-derived) corneal endothelial cells ex vivo: Necrosis to apoptosis switch and up-regulation of bcl-2 and n-cadherin. J Neurochem, 2009, 109(3), 792-806.
185. Delgado, M.; Varela, N.; Gonzalez-Rey, E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia, 2008, 56(10), 1091-1103.
186. de Lanerolle, N.C.; Gunel, M.; Sundaresan, S.; Shen, M.Y.; Brines, M.L.; Spencer, D.D. Vasoactive intestinal polypeptide and its receptor changes in human temporal lobe epilepsy. Brain Res, 1995, 686(2), 182-193.
187. Cunha-Reis, D.; Ribeiro, J.A.; Sebastiao, A.M. Vpac2 receptor activation mediates vip enhancement of population spikes in the ca1 area of the hippocampus. Ann N Y Acad Sci, 2006, 1070, 210-214.
188. Bellamy, J.L.; Cady, R.K.; Durham, P.L. Salivary levels of cgrp and vip in rhinosinusitis and migraine patients. Headache, 2006, 46(1), 24-33.
189. Gutierrez, J.A.; Solenberg, P.J.; Perkins, D.R.; Willency, J.A.; Knierman, M.D.; Jin, Z.; Witcher, D.R.; Luo, S.; Onyia, J.E.; Hale, J.E. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A, 2008, 105(17), 6320-6325.
190. Ferrini, F.; Salio, C.; Lossi, L.; Merighi, A. Ghrelin in central neurons. Curr Neuropharmacol, 2009, 7(1), 37-49.
191. Leung, P.K.; Chow, K.B.; Lau, P.N.; Chu, K.M.; Chan, C.B.; Cheng, C.H.; Wise, H. The truncated ghrelin receptor polypeptide (ghs-r1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal, 2007, 19(5), 1011-1022.
192. Banks, W.A.; Tschop, M.; Robinson, S.M.; Heiman, M.L. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther, 2002, 302(2), 822-827.
193. Portelli, J.; Michotte, Y.; Smolders, I. Ghrelin: An emerging new anticonvulsant neuropeptide. Epilepsia, 2012, 53(4), 585-595.
194. Angelidis, G.; Valotassiou, V.; Georgoulias, P. Current and potential roles of ghrelin in clinical practice. J Endocrinol Invest, 2010, 33(11), 823-838.
195. Lee, J.; Lim, E.; Kim, Y.; Li, E.; Park, S. Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J Endocrinol, 2010, 205(3), 263-270.
196. Zhang, R.; Yang, G.; Wang, Q.; Guo, F.; Wang, H. Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis. Mol Biol Rep, 2013, 40(1), 51-58.
197. Biagini, G.; Torsello, A.; Marinelli, C.; Gualtieri, F.; Vezzali, R.; Coco, S.; Bresciani, E.; Locatelli, V. Beneficial effects of desacylghrelin, hexarelin and ep-80317 in models of status epilepticus. Eur J Pharmacol, 2011, 670(1), 130-136.
198. Chung, H.; Li, E.; Kim, Y.; Kim, S.; Park, S. Multiple signaling pathways mediate ghrelin-induced proliferation of hippocampal neural stem cells. J Endocrinol, 2013.
199. Baatar, D.; Patel, K.; Taub, D.D. The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol, 2011, 340(1), 44-58.
200. Holst, B.; Cygankiewicz, A.; Jensen, T.H.; Ankersen, M.; Schwartz, T.W. High constitutive signaling of the ghrelin receptor- -identification of a potent inverse agonist. Mol Endocrinol, 2003, 17(11), 2201-2210.
201. Portelli, J.; Thielemans, L.; Ver Donck, L.; Loyens, E.; Coppens, J.; Aourz, N.; Aerssens, J.; Vermoesen, K.; Clinckers, R.; Schallier, A.; Michotte, Y.; Moechars, D.; Collingridge, G.L.; Bortolotto, Z.A.; Smolders, I. Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents. Neurotherapeutics, 2012, 9(3), 658-672.
202. Els, S.; Schild, E.; Petersen, P.S.; Kilian, T.M.; Mokrosinski, J.; Frimurer, T.M.; Chollet, C.; Schwartz, T.W.; Holst, B.; Beck-Sickinger, A.G. An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor. J Med Chem, 2012, 55(17), 7437-7449.
203. Mokrosinski, J.; Frimurer, T.M.; Sivertsen, B.; Schwartz, T.W.; Holst, B. Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop. J Biol Chem, 2012, 287(40), 33488-33502.
204. Hassouna, R.; Labarthe, A.; Zizzari, P.; Videau, C.; Culler, M.; Epelbaum, J.; Tolle, V. Actions of agonists and antagonists of the ghrelin/ghs-r pathway on gh secretion, appetite, and cfos activity. Front Endocrinol (Lausanne), 2013, 4, 25.
205. Broglio, F.; Boutignon, F.; Benso, A.; Gottero, C.; Prodam, F.; Arvat, E.; Ghe, C.; Catapano, F.; Torsello, A.; Locatelli, V.; Muccioli, G.; Boeglin, D.; Guerlavais, V.; Fehrentz, J.A.; Martinez, J.; Ghigo, E.; Deghenghi, R. Ep1572: A novel peptido-mimetic gh secretagogue with potent and selective gh-releasing activity in man. J Endocrinol Invest, 2002, 25(8), RC26-28.
206. Piccoli, F.; Degen, L.; MacLean, C.; Peter, S.; Baselgia, L.; Larsen, F.; Beglinger, C.; Drewe, J. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab, 2007, 92(5), 1814-1820.
207. Guerlavais, V.; Boeglin, D.; Mousseaux, D.; Oiry, C.; Heitz, A.; Deghenghi, R.; Locatelli, V.; Torsello, A.; Ghe, C.; Catapano, F.; Muccioli, G.; Galleyrand, J.C.; Fehrentz, J.A.; Martinez, J. New active series of growth hormone secretagogues. J Med Chem, 2003, 46(7), 1191-1203.
208. Peschke, B.; Ankersen, M.; Hansen, T.K.; Hansen, B.S.; Lau, J.; Nielsen, K.K.; Raun, K. New highly potent dipeptidic growth hormone secretagogues with low molecular weight. Eur J Med Chem, 2000, 35(6), 599-618.
209. Moulin, A.; Brunel, L.; Boeglin, D.; Demange, L.; Ryan, J.; M'Kadmi, C.; Denoyelle, S.; Martinez, J.; Fehrentz, J.A. The 1,2,4- triazole as a scaffold for the design of ghrelin receptor ligands: Development of jmv 2959, a potent antagonist. Amino Acids, 2013, 44(2), 301-314.
210. Hansen, B.S.; Raun, K.; Nielsen, K.K.; Johansen, P.B.; Hansen, T.K.; Peschke, B.; Lau, J.; Andersen, P.H.; Ankersen, M. Pharmacological characterisation of a new oral gh secretagogue, nn703. Eur J Endocrinol, 1999, 141(2), 180-189.
211. Holst, B.; Brandt, E.; Bach, A.; Heding, A.; Schwartz, T.W. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol, 2005, 19(9), 2400-2411.
212. Wright, J.W.; Harding, J.W. Brain renin-angiotensin - a new look at an old system. Prog Neurobiol, 2011, 95(1), 49-67.
213. Lenkei, Z.; Palkovits, M.; Corvol, P.; Llorens-Cortes, C. Expression of angiotensin type-1 (at1) and type-2 (at2) receptor mrnas in the adult rat brain: A functional neuroanatomical review. Front Neuroendocrinol, 1997, 18(4), 383-439.
214. Whiting, P.; Nava, S.; Mozley, L.; Eastham, H.; Poat, J. Expression of angiotensin converting enzyme mrna in rat brain. Brain Res Mol Brain Res, 1991, 11(1), 93-96.
215. Sirett, N.E.; Bray, J.J.; Hubbard, J.I. Localization of immunoreactive angiotensin ii in the hippocampus and striatum of rat brain. Brain Res, 1981, 217(2), 405-411.
216. Haas, H.L.; Felix, D.; Celio, M.R.; Inagami, T. Angiotensin ii in the hippocampus. A histochemical and electrophysiological study. Experientia, 1980, 36(12), 1394-1395.
217. Gouveia, T.L.; Frangiotti, M.I.; de Brito, J.M.; de Castro Neto, E.F.; Sakata, M.M.; Febba, A.C.; Casarini, D.E.; Amado, D.; Cavalheiro, E.A.; Almeida, S.S.; Manchini, M.T.; Araujo, R.C.; Silva, J.A., Jr.; Naffah-Mazzacoratti Mda, G. The levels of reninangiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Neurochem Int, 2012, 61(1), 54-62.
218. Pereira, M.G.; Becari, C.; Oliveira, J.A.; Salgado, M.C.; Garcia-Cairasco, N.; Costa-Neto, C.M. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond), 2010, 119(11), 477-482.
219. Arganaraz, G.A.; Konno, A.C.; Perosa, S.R.; Santiago, J.F.; Boim, M.A.; Vidotti, D.B.; Varella, P.P.; Costa, L.G.; Canzian, M.; Porcionatto, M.A.; Yacubian, E.M.; Sakamoto, A.C.; Carrete, H., Jr.; Centeno, R.S.; Amado, D.; Cavalheiro, E.A.; Junior, J.A.; Mazzacoratti Mda, G. The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia, 2008, 49(8), 1348-1357.
220. Georgiev, V.P.; Petkova, B.P.; Petkov, V.D.; Kambourova, T.S. Interactions of angiotensin ii and gaba-ergic agents at the threshold of convulsive reactions. Acta Physiol Pharmacol Bulg, 1986, 12(2), 14-20.
221. Tchekalarova, J.; Georgiev, V. Angiotensin peptides modulatory system: How is it implicated in the control of seizure susceptibility? Life Sci, 2005, 76(9), 955-970.
222. De Bundel, D.; Smolders, I.; Vanderheyden, P.; Michotte, Y. Ang ii and ang iv: Unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci Ther, 2008, 14(4), 315-339.
223. Stragier, B.; Clinckers, R.; Meurs, A.; De Bundel, D.; Sarre, S.; Ebinger, G.; Michotte, Y.; Smolders, I. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin iv against pilocarpine-induced limbic seizures in rats. J Neurochem, 2006, 98(4), 1100-1113.
224. Pechlivanova, D.M.; Stoynev, A.G.; Tchekalarova, J.D. The effects of chronic losartan pretreatment on restraint stress-induced changes in motor activity, nociception and pentylenetetrazol generalized seizures in rats. Folia Med (Plovdiv), 2011, 53(2), 69-73.
225. Lukawski, K.; Janowska, A.; Jakubus, T.; Czuczwar, S.J. Interactions between angiotensin at receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock. Fundam Clin Pharmacol, 2013.
226. Lukawski, K.; Janowska, A.; Jakubus, T.; Tochman-Gawda, A.; Czuczwar, S.J. Angiotensin at1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur J Pharmacol, 2010, 640(1-3), 172-177.
227. Sarro, G.D.; Paola, E.D.; Gratteri, S.; Gareri, P.; Rispoli, V.; Siniscalchi, A.; Tripepi, G.; Gallelli, L.; Citraro, R.; Russo, E. Fosinopril and zofenopril, two angiotensin-converting enzyme (ace) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in dba/2 mice. Pharmacol Res, 2012, 65(3), 285-296.
228. Hadjiivanova, C.H.; Georgiev, V. In vitro effect of angiotensin ii on gaba release in rat hippocampus. Neuropeptides, 1998, 32(5), 431-434.
229. Tchekalarova, J.; Kambourova, T.; Georgiev, V. Effects of angiotensin iii and angiotensin iv on pentylenetetrazol seizure susceptibility (threshold and kindling): Interaction with adenosine a(1) receptors. Brain Res Bull, 2001, 56(2), 87-91.
230. Kovacs, Z.; Dobolyi, A.; Juhasz, G.; Kekesi, K.A. Nucleoside map of the human central nervous system. Neurochem Res, 2010, 35(3), 452-464.
231. Kovacs, Z.; Juhasz, G.; Palkovits, M.; Dobolyi, A.; Kekesi, K.A. Area, age and gender dependence of the nucleoside system in the brain: A review of current literature. Curr Top Med Chem, 2011, 11(8), 1012-1033.
232. Vanderheyden, P.M. From angiotensin iv binding site to at4 receptor. Mol Cell Endocrinol, 2009, 302(2), 159-166.
233. Chai, S.Y.; Fernando, R.; Peck, G.; Ye, S.Y.; Mendelsohn, F.A.; Jenkins, T.A.; Albiston, A.L. The angiotensin iv/at4 receptor. Cell Mol Life Sci, 2004, 61(21), 2728-2737.
234. Benoist, C.C.; Wright, J.W.; Zhu, M.; Appleyard, S.M.; Wayman, G.A.; Harding, J.W. Facilitation of hippocampal synaptogenesis and spatial memory by c-terminal truncated nle1-angiotensin iv analogs. J Pharmacol Exp Ther, 2011, 339(1), 35-44.
235. McCoy, A.T.; Benoist, C.C.; Wright, J.W.; Kawas, L.H.; Bule-Ghogare, J.M.; Zhu, M.; Appleyard, S.M.; Wayman, G.A.; Harding, J.W. Evaluation of metabolically stabilized angiotensin iv analogs as procognitive/antidementia agents. J Pharmacol Exp Ther, 2013, 344(1), 141-154.
236. Grossman, A.; Costa, A. The regulation of hypothalamic crh: Impact of in vitro studies on the central control of the stress response. Funct Neurol, 1993, 8(5), 325-334.
237. Gallagher, J.P.; Orozco-Cabal, L.F.; Liu, J.; Shinnick-Gallagher, P. Synaptic physiology of central crh system. Eur J Pharmacol, 2008, 583(2-3), 215-225.
238. Pilcher, W.H.; Joseph, S.A. Co-localization of crf-ir perikarya and acth-ir fibers in rat brain. Brain Res, 1984, 299(1), 91-102.
239. Pranzatelli, M.R. On the molecular mechanism of adrenocorticotrophic hormone in the cns: Neurotransmitters and receptors. Exp Neurol, 1994, 125(1), 142-161.
240. Yan, X.X.; Toth, Z.; Schultz, L.; Ribak, C.E.; Baram, T.Z. Corticotropin-releasing hormone (crh)-containing neurons in the immature rat hippocampal formation: Light and electron microscopic features and colocalization with glutamate decarboxylase and parvalbumin. Hippocampus, 1998, 8(3), 231-243.
241. Baram, T.Z.; Yi, S.; Avishai-Eliner, S.; Schultz, L. Development neurobiology of the stress response: Multilevel regulation of corticotropin-releasing hormone function. Ann N Y Acad Sci, 1997, 814, 252-265.
242. Wu, J.; Ma, D.L.; Ling, E.A.; Tang, F.R. Corticotropin releasing factor (crf) in the hippocampus of the mouse pilocarpine model of status epilepticus. Neurosci Lett, 2012, 512(2), 83-88.
243. Smith, M.A.; Weiss, S.R.; Abedin, T.; Kim, H.; Post, R.M.; Gold, P.W. Effects of amygdala kindling and electroconvulsive seizures on the expression of corticotropin-releasing hormone in the rat brain. Mol Cell Neurosci, 1991, 2(2), 103-116.
244. Smith, M.A.; Weiss, S.R.; Berry, R.L.; Zhang, L.X.; Clark, M.; Massenburg, G.; Post, R.M. Amygdala-kindled seizures increase the expression of corticotropin-releasing factor (crf) and crfbinding protein in gabaergic interneurons of the dentate hilus. Brain Res, 1997, 745(1-2), 248-256.
245. Piekut, D.T.; Phipps, B. Corticotropin-releasing factor - immunolabeled fibers in brain regions with localized kainate neurotoxicity. Acta Neuropathol, 1999, 98(6), 622-628.
246. Foradori, C.D.; Lund, T.D.; Nagahara, A.H.; Koenig, J.I.; Handa, R.J. Corticotropin-releasing hormone heterogeneous nuclear rna (hnrna) and immunoreactivity are induced in extrahypothalamic brain sites by kainic-acid-induced seizures and are modulated by estrogen. Brain Res, 2007, 1164, 44-54.
247. Piekut, D.T.; Phipps, B. Increased corticotropin-releasing factor immunoreactivity in select brain sites following kainate elicited seizures. Brain Res, 1998, 781(1-2), 100-113.
248. Hatalski, C.G.; Brunson, K.L.; Tantayanubutr, B.; Chen, Y.; Baram, T.Z. Neuronal activity and stress differentially regulate hippocampal and hypothalamic corticotropin-releasing hormone expression in the immature rat. Neuroscience, 2000, 101(3), 571-580.
249. Baram, T.Z.; Schultz, L. Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res Dev Brain Res, 1991, 61(1), 97-101.
250. Brunson, K.L.; Schultz, L.; Baram, T.Z. The in vivo proconvulsant effects of corticotropin releasing hormone in the developing rat are independent of ionotropic glutamate receptor activation. Brain Res Dev Brain Res, 1998, 111(1), 119-128.
251. Ribak, C.E.; Baram, T.Z. Selective death of hippocampal ca3 pyramidal cells with mossy fiber afferents after crh-induced status epilepticus in infant rats. Brain Res Dev Brain Res, 1996, 91(2), 245-251.
252. Hollrigel, G.S.; Chen, K.; Baram, T.Z.; Soltesz, I. The proconvulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience, 1998, 84(1), 71-79.
253. Baram, T.Z.; Hirsch, E.; Snead, O.C., 3rd; Schultz, L. Corticotropin-releasing hormone-induced seizures in infant rats originate in the amygdala. Ann Neurol, 1992, 31(5), 488-494.
254. Pascual, J.; Heinrichs, S.C. Olfactory neophobia and seizure susceptibility phenotypes in an animal model of epilepsy are normalized by impairment of brain corticotropin releasing factor. Epilepsia, 2007, 48(4), 827-833.
255. Baram, T.Z.; Koutsoukos, Y.; Schultz, L.; Rivier, J. The effect of 'astressin', a novel antagonist of corticotropin releasing hormone (crh), on crh-induced seizures in the infant rat: Comparison with two other antagonists. Mol Psychiatry, 1996, 1(3), 223-226.
256. Maecker, H.; Desai, A.; Dash, R.; Rivier, J.; Vale, W.; Sapolsky, R. Astressin, a novel and potent crf antagonist, is neuroprotective in the hippocampus when administered after a seizure. Brain Res, 1997, 744(1), 166-170.
257. Combi, R.; Dalpra, L.; Ferini-Strambi, L.; Tenchini, M.L. Frontal lobe epilepsy and mutations of the corticotropin-releasing hormone gene. Ann Neurol, 2005, 58(6), 899-904.
258. Sansoni, V.; Forcella, M.; Mozzi, A.; Fusi, P.; Ambrosini, R.; Ferini-Strambi, L.; Combi, R. Functional characterization of a crh missense mutation identified in an adnfle family. PLoS One, 2013, 8(4), e61306.
259. Lerman, P.; Kivity, S. The efficacy of corticotropin in primary infantile spasms. J Pediatr, 1982, 101(2), 294-296.
260. Hrachovy, R.A.; Frost, J.D., Jr.; Glaze, D.G. High-dose, longduration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr, 1994, 124(5 Pt 1), 803-806.
261. Dooley, J.M.; Camfield, P.R.; Goulden, K.J.; Macken, S.R. Lowdose alternate-day corticotropin therapy in the treatment of childhood seizures. Am J Dis Child, 1989, 143(11), 1263-1265.
262. Baram, T.Z.; Mitchell, W.G.; Tournay, A.; Snead, O.C.; Hanson, R.A.; Horton, E.J. High-dose corticotropin (acth) versus prednisone for infantile spasms: A prospective, randomized, blinded study. Pediatrics, 1996, 97(3), 375-379.
263. Brunson, K.L.; Khan, N.; Eghbal-Ahmadi, M.; Baram, T.Z. Corticotropin (acth) acts directly on amygdala neurons to downregulate corticotropin-releasing hormone gene expression. Ann Neurol, 2001, 49(3), 304-312.
264. Wang, W.; Murphy, B.; Dow, K.E.; David Andrew, R.; Fraser, D.D. Systemic adrenocorticotropic hormone administration downregulates the expression of corticotropin-releasing hormone (crh) and crh-binding protein in infant rat hippocampus. Pediatr Res, 2004, 55(4), 604-610.
265. Baram, T.Z.; Schultz, L. Acth does not control neonatal seizures induced by administration of exogenous corticotropin-releasing hormone. Epilepsia, 1995, 36(2), 174-178.
266. Avishai-Eliner, S.; Yi, S.J.; Baram, T.Z. Developmental profile of messenger rna for the corticotropin-releasing hormone receptor in the rat limbic system. Brain Res Dev Brain Res, 1996, 91(2), 159-163.
267. Brunson, K.L.; Eghbal-Ahmadi, M.; Baram, T.Z. How do the many etiologies of west syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev, 2001, 23(7), 533-538.
268. Holmes, M.C.; Catt, K.J.; Aguilera, G. Involvement of vasopressin in the down-regulation of pituitary corticotropin-releasing factor receptors after adrenalectomy. Endocrinology, 1987, 121(6), 2093-2098.
269. Grammatopoulos, D.K. Insights into mechanisms of corticotropinreleasing hormone receptor signal transduction. Br J Pharmacol, 2012, 166(1), 85-97.
270. Wang, W.; Dow, K.E.; Fraser, D.D. Elevated corticotropin releasing hormone/corticotropin releasing hormone-r1 expression in postmortem brain obtained from children with generalized epilepsy. Ann Neurol, 2001, 50(3), 404-409.
271. Baram, T.Z.; Chalmers, D.T.; Chen, C.; Koutsoukos, Y.; De Souza, E.B. The crf1 receptor mediates the excitatory actions of corticotropin releasing factor (crf) in the developing rat brain: In vivo evidence using a novel, selective, non-peptide crf receptor antagonist. Brain Res, 1997, 770(1-2), 89-95.
272. Bobele, G.B.; Ward, K.E.; Bodensteiner, J.B. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child, 1993, 147(2), 223-225.
273. Zorrilla, E.P.; Koob, G.F. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today, 2010, 15(9-10), 371-383.
274. Liang, L.; Angleson, J.K.; Dores, R.M. Using the human melanocortin-2 receptor as a model for analyzing hormone/receptor interactions between a mammalian mc2 receptor and acth(1-24). Gen Comp Endocrinol, 2013, 181, 203-210.
275. Jaworska-Feil, L.; Turchan, J.; Przewlocka, B.; Budziszewska, B.; Leskiewicz, M.; Lason, W. Effects of pilocarpine- and kainateinduced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain. J Neural Transm, 1999, 106(5-6), 395-407.
276. Knoblach, S.M.; Kubek, M.J. Thyrotropin-releasing hormone release is enhanced in hippocampal slices after electroconvulsive shock. J Neurochem, 1994, 62(1), 119-125.
277. Deng, P.Y.; Porter, J.E.; Shin, H.S.; Lei, S. Thyrotropin-releasing hormone increases gaba release in rat hippocampus. J Physiol, 2006, 577(Pt 2), 497-511.
278. Nie, Y.; Schoepp, D.D.; Klaunig, J.E.; Yard, M.; Lahiri, D.K.; Kubek, M.J. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res, 2005, 1054(1), 45-54.
279. Yatsugi, S.; Yamamoto, M. Anticonvulsive properties of ym- 14673, a new trh analogue, in amygdaloid-kindled rats. Pharmacol Biochem Behav, 1991, 38(3), 669-672.
280. Osonoe, K.; Osonoe, M.; Ariga, K.; Mori, N. The effect of thyrotropin-releasing hormone (trh) on limbic status epilepticus in rats. Epilepsy Res, 1994, 18(3), 217-225.
281. Ujihara, H.; Xie, R.M.; Sasa, M.; Ishihara, K.; Fujita, Y.; Yoshimura, M.; Kishimoto, T.; Serikawa, T.; Yamada, J.; Takaori, S. Inhibition by thyrotropin-releasing hormone of epileptic seizures in spontaneously epileptic rats. Eur J Pharmacol, 1991, 196(1), 15-19.
282. Przewlocka, B.; Labuz, D.; Mika, J.; Lipkowski, A.; van Luijtelaar, G.; Coenen, A.; Lason, W. Protective effects of trh and its analogues in chemical and genetic models of seizures. Pol J Pharmacol, 1997, 49(5), 373-378.
283. Takeuchi, Y.; Takano, T.; Abe, J.; Takikita, S.; Ohno, M. Thyrotropin-releasing hormone: Role in the treatment of west syndrome and related epileptic encephalopathies. Brain Dev, 2001, 23(7), 662-667.
284. Tanaka, C.; Maegaki, Y.; Koeda, T.; Ohta, S.; Takeshita, K. Successful treatment of progressive myoclonus epilepsy with trh. Pediatr Neurol, 1998, 18(5), 442-444.
285. Matsumoto, A.; Kumagai, T.; Takeuchi, T.; Miyazaki, S.; Watanabe, K. Clinical effects of thyrotropin-releasing hormone for severe epilepsy in childhood: A comparative study with acth therapy. Epilepsia, 1987, 28(1), 49-55.
286. Kubek, M.J.; Liang, D.; Byrd, K.E.; Domb, A.J. Prolonged seizure suppression by a single implantable polymeric-trh microdisk preparation. Brain Res, 1998, 809(2), 189-197.
287. Veronesi, M.C.; Kubek, D.J.; Kubek, M.J. Intranasal delivery of a thyrotropin-releasing hormone analog attenuates seizures in the amygdala-kindled rat. Epilepsia, 2007, 48(12), 2280-2286.
288. Kubek, M.J.; Domb, A.J.; Veronesi, M.C. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics, 2009, 6(2), 359-371.
289. Heuer, H.; Schafer, M.K.; O'Donnell, D.; Walker, P.; Bauer, K. Expression of thyrotropin-releasing hormone receptor 2 (trh-r2) in the central nervous system of rats. J Comp Neurol, 2000, 428(2), 319-336.
290. Gary, K.A.; Sevarino, K.A.; Yarbrough, G.G.; Prange, A.J., Jr.; Winokur, A. The thyrotropin-releasing hormone (trh) hypothesis of homeostatic regulation: Implications for trh-based therapeutics. J Pharmacol Exp Ther, 2003, 305(2), 410-416.
291. Inanaga, K.; Kumashiro, H.; Fukuyama, Y.; Ohtahara, S.; Shirouzu, M. Clinical study of oral administration of dn-1417, a trh analog, in patients with intractable epilepsy. Epilepsia, 1989, 30(4), 438-445.
292. Renming, X.; Ishihara, K.; Sasa, M.; Ujihara, H.; Momiyama, T.; Fujita, Y.; Todo, N.; Serikawa, T.; Yamada, J.; Takaori, S. Antiepileptic effects of cnk-602a, a novel thyrotropin-releasing hormone analog, on absence-like and tonic seizures of spontaneously epileptic rats. Eur J Pharmacol, 1992, 223(2-3), 185-192.
293. Momiyama, T.; Ishihara, K.; Kimura, K.; Todo, N.; Fujita, Y.; Serikawa, T.; Sasa, M. Long-term antiepileptic effects of chronic intake of cnk-602a, a thyrotropin-releasing hormone analogue, on spontaneously epileptic rats. Epilepsia, 1996, 37(4), 328-331.
294. Rajput, S.K.; Singh, J.N.; Ingole, S.; Jain, G.; Kaur, N.; Monga, V.; Meena, C.L.; Jain, R.; Sharma, S.S. Neuropharmacological profile of l-pglu-(1-benzyl)-l-his-l-pronh2, a newer thyrotropin-releasing hormone analog: Effects on seizure models, sodium current, cerebral blood flow and behavioral parameters. Epilepsy Res, 2009, 87(2-3), 223-233.
295. Rajput, S.K.; Krishnamoorthy, S.; Pawar, C.; Kaur, N.; Monga, V.; Meena, C.L.; Jain, R.; Sharma, S.S. Antiepileptic potential and behavioral profile of l-pglu-(2-propyl)-l-his-l-pronh2, a newer thyrotropin-releasing hormone analog. Epilepsy Behav, 2009, 14(1), 48-53.
296. Sah, N.; Rajput, S.K.; Singh, J.N.; Meena, C.L.; Jain, R.; Sikdar, S.K.; Sharma, S.S. L-pglu-(2-propyl)-l-his-l-pronh(2) attenuates 4- aminopyridine-induced epileptiform activity and sodium current: A possible action of new thyrotropin-releasing hormone analog for its anticonvulsant potential. Neuroscience, 2011, 199, 74-85.
297. Lee, H.J.; Macbeth, A.H.; Pagani, J.H.; Young, W.S., 3rd Oxytocin: The great facilitator of life. Prog Neurobiol, 2009, 88(2), 127-151.
298. Caffe, A.R.; Van Ryen, P.C.; Van der Woude, T.P.; Van Leeuwen, F.W. Vasopressin and oxytocin systems in the brain and upper spinal cord of macaca fascicularis. J Comp Neurol, 1989, 287(3), 302-325.
299. Knobloch, H.S.; Charlet, A.; Hoffmann, L.C.; Eliava, M.; Khrulev, S.; Cetin, A.H.; Osten, P.; Schwarz, M.K.; Seeburg, P.H.; Stoop, R.; Grinevich, V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron, 2012, 73(3), 553-566.
300. Zhang, L.; Hernandez, V.S. Synaptic innervation to rat hippocampus by vasopressin-immuno-positive fibres from the hypothalamic supraoptic and paraventricular nuclei. Neuroscience, 2013, 228, 139-162.
301. Sun, Q.; Pretel, S.; Applegate, C.D.; Piekut, D.T. Oxytocin and vasopressin mrna expression in rat hypothalamus following kainic acid-induced seizures. Neuroscience, 1996, 71(2), 543-554.
302. Loyens, E.; Vermoesen, K.; Schallier, A.; Michotte, Y.; Smolders, I. Proconvulsive effects of oxytocin in the generalized pentylenetetrazol mouse model are mediated by vasopressin 1a receptors. Brain Res, 2012, 1436, 43-50.
303. Erbas, O.; Yilmaz, M.; Korkmaz, H.A.; Bora, S.; Evren, V.; Peker, G. Oxytocin inhibits pentylentetrazol-induced seizures in the rat. Peptides, 2013, 40, 141-144.
304. Zaninetti, M.; Raggenbass, M. Oxytocin receptor agonists enhance inhibitory synaptic transmission in the rat hippocampus by activating interneurons in stratum pyramidale. Eur J Neurosci, 2000, 12(11), 3975-3984.
305. Raggenbass, M.; Wuarin, J.P.; Gahwiler, B.H.; Dreifuss, J.J. Opposing effects of oxytocin and of a mu-receptor agonistic opioid peptide on the same class of non-pyramidal neurones in rat hippocampus. Brain Res, 1985, 344(2), 392-396.
306. Croiset, G.; De Wied, D. Proconvulsive effect of vasopressin; mediation by a putative v2 receptor subtype in the central nervous system. Brain Res, 1997, 759(1), 18-23.
307. Brinton, R.E.; McEwen, B.S. Vasopressin neuromodulation in the hippocampus. J Neurosci, 1989, 9(3), 752-759.
308. Muhlethaler, M.; Dreifuss, J.J.; Gahwiler, B.H. Vasopressin excites hippocampal neurones. Nature, 1982, 296(5859), 749-751.
309. Chapman, C.D.; Frey, W.H., 2nd; Craft, S.; Danielyan, L.; Hallschmid, M.; Schioth, H.B.; Benedict, C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res, 2012.
310. Neumann, I.D.; Maloumby, R.; Beiderbeck, D.I.; Lukas, M.; Landgraf, R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology, 2013.
311. Zhu, J.; Jiang, Y.; Xu, G.; Liu, X. Intranasal administration: A potential solution for cross-bbb delivering neurotrophic factors. Histol Histopathol, 2012, 27(5), 537-548.
312. Stoop, R. Neuromodulation by oxytocin and vasopressin. Neuron, 2012, 76(1), 142-159.
313. Young, W.S.; Li, J.; Wersinger, S.R.; Palkovits, M. The vasopressin 1b receptor is prominent in the hippocampal area ca2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience, 2006, 143(4), 1031-1039.
314. Paban, V.; Alescio-Lautier, B.; Devigne, C.; Soumireu-Mourat, B. The behavioral effect of vasopressin in the ventral hippocampus is antagonized by an oxytocin receptor antagonist. Eur J Pharmacol, 1998, 361(2-3), 165-173.
315. Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol, 2012, 24(4), 609-628.
316. Hicks, C.; Jorgensen, W.; Brown, C.; Fardell, J.; Koehbach, J.; Gruber, C.W.; Kassiou, M.; Hunt, G.E.; McGregor, I.S. The nonpeptide oxytocin receptor agonist way 267,464: Receptorbinding profile, prosocial effects and distribution of c-fos expression in adolescent rats. J Neuroendocrinol, 2012, 24(7), 1012-1029.
317. Decaux, G.; Soupart, A.; Vassart, G. Non-peptide argininevasopressin antagonists: The vaptans. Lancet, 2008, 371(9624), 1624-1632.
318. Pitt, G.R.; Batt, A.R.; Haigh, R.M.; Penson, A.M.; Robson, P.A.; Rooker, D.P.; Tartar, A.L.; Trim, J.E.; Yea, C.M.; Roe, M.B. Nonpeptide oxytocin agonists. Bioorg Med Chem Lett, 2004, 14(17), 4585-4589.
319. Mazarati, A.M.; Hohmann, J.G.; Bacon, A.; Liu, H.; Sankar, R.; Steiner, R.A.; Wynick, D.; Wasterlain, C.G. Modulation of hippocampal excitability and seizures by galanin. J Neurosci, 2000, 20(16), 6276-6281.
320. Wasterlain, C.G.; Mazarati, A.M.; Naylor, D.; Niquet, J.; Liu, H.; Suchomelova, L.; Baldwin, R.; Katsumori, H.; Shirasaka, Y.; Shin, D.; Sankar, R. Short-term plasticity of hippocampal neuropeptides and neuronal circuitry in experimental status epilepticus. Epilepsia, 2002, 43 Suppl 5, 20-29.
321. Robertson, C.R.; Flynn, S.P.; White, H.S.; Bulaj, G. Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat Prod Rep, 2011, 28(4), 741-762.